Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen and RheoGene Enter Into Non-Exclusive Licensing Deal

NEW YORK, Aug. 1 (GenomeWeb News) - Cellumen and RheoGene announced last week that they have entered into a non-exclusive commercial licensing agreement under which Cellumen will use RheoGene's RheoSwitch inducible gene regulation technology to develop cell biology screening products.

 

The products will include reagents for high content screening and stable cell lines. In addition, the companies will collaborate on the development and validation of mammalian cell lines to be used in Cellumen's cell biology profiling assays.

 

Financial terms of the deal were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.